Horizon Space Acquisition II SPAC to merge with SL Bio at $5.568B enterprise value

Horizon Space Acquisition II Corp.

SL Bio develops cellular and gene therapies; will become wholly owned sub of PubCo via two-step merger.
SPAC shareholders to receive one PubCo ordinary share per share; SL Bio holders get shares based on $5.568B / $10.00 ratio.
Transactions require approvals from both companies' shareholders, Nasdaq listing, and regulatory clearances.
Sponsor and certain SL Bio shareholders enter lock-up; shares restricted until 150 days post-close or $12.00 trigger.
Sponsor support agreement ensures voting in favor; shareholder support agreement covers key SL Bio holders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.